Skip to main content
. 2017 Feb 4;8(9):14283–14293. doi: 10.18632/oncotarget.15093

Figure 2. MMP2 and MMP9 are targets of HuR.

Figure 2

A. Schematic representations of predicted AREs in the 3’ UTR of MMP2 and MMP9 mRNAs are depicted. B. RNA immunoprecipitation was carried out with the anti-HuR antibody or control IgG. Lanes 1 and 5, no template PCR control; lanes 2 and 6, IgG RNA immunoprecipitation; lanes 3 and 7, Anti-HuR RNA immunoprecipitation; and lanes 4 and 8, 10% input. C. and D. MOVAS cells were transfected with LacZ or HuR plasmid for 24 hours and then treated with actinomycin D (5 μg/mL). The levels of MMP2 (C) and MMP9 (D) mRNAs were determined by real-time PCR (n = 4). E. Western blot analysis to detect MMP2 and MMP9 expression in MOVAS cells after LacZ or HuR transfection. F. Quantitative analysis of MMP2 and MMP9 protein levels in SMCs (n = 4). *p < 0.05 vs LacZ.